brain tumor glioma
Conditions
Interventions
None listed
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients scheduled for brain MRI with contrast injection as part of the clinical diagnostic procedure (cohort 1), patients diagnosed with suspected glioma scheduled for brain MRI as part of the clinical diagnostic procedure (cohort 2), patients with (suspected) glioma referred for biopsy or resection (cohort 3). Age 18 years or older. Signed informed consent.
Exclusion criteria
Exclusion criteria: Contra-indications for an MRI exam. Reduced kidney function. Pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The endpoint of the first part of the study is a novel MRI protocol for characterization of the vessel architecture, assessed with respect to the signal-to-noise ratio (SNR) and the ability to obtain vascular information. The main parameters that will be used for characterization of the vasculature are physiological parameters including the vessel architecture, cerebral blood volume (CBV), cerebral blood flow (CBF), mean transit time (MTT), and oxygenation level. The main study end point of the second part of the study is the accuracy of automatic classification of the tumor*s genotype. The accuracy of the new method will be compared to the current state-of-the-art reference method based on conventional MRI. | — |
Secondary
| Measure | Time frame |
|---|---|
| Baseline characteristics of subjects (including age, sex, Karnofsky performance status, tumor histology, molecular parameters (1p/19q, Isocitrate Dehydrogenase (IDH1/2) and O6-Methylguanine-DNA Methyltransferase (MGMT) status), tumor location, supportive and antitumor treatment). In addition, the outcome (e.g. mortality, tumor progression, radiation necrosis, functioning of patients) will be used as study parameter. The outcome will be determined from the follow-up scans after 3 and 6 months, where the criterion for progression or pseudo-progression is determined by the outcome of the scan. | — |
Countries
Netherlands
Outcome results
None listed